Nucleic acid aptamer controls mycoplasma infection for inhibiting the malignancy of esophageal squamous cell carcinoma
Yibin Zhang,Hui Zhang,Xing Sun,Tianhuan Peng,Tiantian Xie,Yijun Yuan,Junxiao Guo,Yinglei Chen,Lingli Zhou,Neng Ling,Hui Li,Ling Li,Lin Zhang,Xiaodong Li,Long Liang,Jing Liu,Mao Ye,Weihong Tan
DOI: https://doi.org/10.1016/j.ymthe.2022.02.018
IF: 12.91
2022-02-01
Molecular Therapy
Abstract:Esophageal cancer is one of the most frequent malignant tumors of the digestive tract, among which esophageal squamous cell carcinoma (ESCC) is the main pathological type worldwide. Previous studies have shown microbial infections in the upper digestive tract to be a potential risk factor in ESCC etiology. In this study, we identified that Mycoplasma hyorhinis infection promoted the malignancy of ESCC. In response, we generated a single-stranded DNA aptamer, ZY3A, against M. hyorhinis using the cell-SELEX strategy. The underlying recognition mechanism of ZY3A on M. hyorhinis involves its binding to M. hyorhinis-specific p37 protein. This tool allowed us to provide the first proof-of-concept evidence using a nucleic acid aptamer to control mycoplasma infection. More specifically, we found that ZY3A could neutralize M. hyorhinis infection on ESCC cells by blocking the interaction between p37 protein and its receptor TLR4 on the ESCC cell membrane. As a result, ZY3A inhibited the migration and invasion of M. hyorhinis-infected ESCC cells in vitro and metastasis in vivo. Taken together, these findings indicate that aptamer ZY3A is a potential candidate for development into a novel molecular tool for treatment of M. hyorhinis infection and a safe first-in-class M. hyorhinis-targeting antitumor agent.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology